Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 94

1.

Humoral immunity and delayed-type hypersensitivity in healthy subjects treated for 30 days with MK-7123, a selective CXCR2 antagonist.

Seiberling M, Kamtchoua T, Stryszak P, Ma X, Langdon RB, Khalilieh S.

Int Immunopharmacol. 2013 Oct;17(2):178-83. doi: 10.1016/j.intimp.2013.05.029. Epub 2013 Jun 19.

PMID:
23791619
[PubMed - indexed for MEDLINE]
2.

SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects.

Holz O, Khalilieh S, Ludwig-Sengpiel A, Watz H, Stryszak P, Soni P, Tsai M, Sadeh J, Magnussen H.

Eur Respir J. 2010 Mar;35(3):564-70. doi: 10.1183/09031936.00048509. Epub 2009 Jul 30.

PMID:
19643947
[PubMed - indexed for MEDLINE]
Free Article
3.

Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial.

Nair P, Gaga M, Zervas E, Alagha K, Hargreave FE, O'Byrne PM, Stryszak P, Gann L, Sadeh J, Chanez P; Study Investigators.

Clin Exp Allergy. 2012 Jul;42(7):1097-103. doi: 10.1111/j.1365-2222.2012.04014.x.

PMID:
22702508
[PubMed - indexed for MEDLINE]
4.

SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans.

Lazaar AL, Sweeney LE, MacDonald AJ, Alexis NE, Chen C, Tal-Singer R.

Br J Clin Pharmacol. 2011 Aug;72(2):282-93. doi: 10.1111/j.1365-2125.2011.03968.x.

PMID:
21426372
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Neutrophil chemotaxis caused by chronic obstructive pulmonary disease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2.

Kaur M, Singh D.

J Pharmacol Exp Ther. 2013 Oct;347(1):173-80. doi: 10.1124/jpet.112.201855. Epub 2013 Aug 2.

PMID:
23912333
[PubMed - indexed for MEDLINE]
Free Article
6.

Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine.

Hsueh EC, Gupta RK, Qi K, Morton DL.

J Clin Oncol. 1998 Sep;16(9):2913-20.

PMID:
9738558
[PubMed - indexed for MEDLINE]
7.

A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation.

Chapman RW, Minnicozzi M, Celly CS, Phillips JE, Kung TT, Hipkin RW, Fan X, Rindgen D, Deno G, Bond R, Gonsiorek W, Billah MM, Fine JS, Hey JA.

J Pharmacol Exp Ther. 2007 Aug;322(2):486-93. Epub 2007 May 11.

PMID:
17496165
[PubMed - indexed for MEDLINE]
Free Article
8.

A novel flow cytometric assay of human whole blood neutrophil and monocyte CD11b levels: upregulation by chemokines is related to receptor expression, comparison with neutrophil shape change, and effects of a chemokine receptor (CXCR2) antagonist.

Nicholson GC, Tennant RC, Carpenter DC, Sarau HM, Kon OM, Barnes PJ, Salmon M, Vessey RS, Tal-Singer R, Hansel TT.

Pulm Pharmacol Ther. 2007;20(1):52-9. Epub 2006 Jan 6.

PMID:
16406722
[PubMed - indexed for MEDLINE]
9.

Vitamin E supplementation and in vivo immune response in healthy elderly subjects. A randomized controlled trial.

Meydani SN, Meydani M, Blumberg JB, Leka LS, Siber G, Loszewski R, Thompson C, Pedrosa MC, Diamond RD, Stollar BD.

JAMA. 1997 May 7;277(17):1380-6.

PMID:
9134944
[PubMed - indexed for MEDLINE]
10.

Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis.

Singh S, Sadanandam A, Nannuru KC, Varney ML, Mayer-Ezell R, Bond R, Singh RK.

Clin Cancer Res. 2009 Apr 1;15(7):2380-6. doi: 10.1158/1078-0432.CCR-08-2387. Epub 2009 Mar 17.

PMID:
19293256
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Screening for hepatitis A and B antibodies in patients with chronic liver disease.

Lau DT, Hewlett AT.

Am J Med. 2005 Oct;118 Suppl 10A:28S-33S. Review.

PMID:
16271538
[PubMed - indexed for MEDLINE]
12.

LPS challenge in healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2.

Aul R, Patel S, Summerhill S, Kilty I, Plumb J, Singh D.

Int Immunopharmacol. 2012 Jul;13(3):225-31. doi: 10.1016/j.intimp.2012.04.008. Epub 2012 May 2.

PMID:
22561413
[PubMed - indexed for MEDLINE]
13.

The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models.

Ning Y, Labonte MJ, Zhang W, Bohanes PO, Gerger A, Yang D, Benhaim L, Paez D, Rosenberg DO, Nagulapalli Venkata KC, Louie SG, Petasis NA, Ladner RD, Lenz HJ.

Mol Cancer Ther. 2012 Jun;11(6):1353-64. doi: 10.1158/1535-7163.MCT-11-0915. Epub 2012 Mar 5.

PMID:
22391039
[PubMed - indexed for MEDLINE]
Free Article
14.

Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.

Gonsiorek W, Fan X, Hesk D, Fossetta J, Qiu H, Jakway J, Billah M, Dwyer M, Chao J, Deno G, Taveras A, Lundell DJ, Hipkin RW.

J Pharmacol Exp Ther. 2007 Aug;322(2):477-85. Epub 2007 May 11.

PMID:
17496166
[PubMed - indexed for MEDLINE]
Free Article
15.

Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.

Vandepapelière P, Horsmans Y, Moris P, Van Mechelen M, Janssens M, Koutsoukos M, Van Belle P, Clement F, Hanon E, Wettendorff M, Garçon N, Leroux-Roels G.

Vaccine. 2008 Mar 4;26(10):1375-86. doi: 10.1016/j.vaccine.2007.12.038. Epub 2008 Jan 14.

PMID:
18272264
[PubMed - indexed for MEDLINE]
16.

[Vaccination against viral hepatitis A and B in adults aged over 40 years--antibody persistence and immune memory].

Chlibek R, Smetana J, Bostíková V, Splino M.

Epidemiol Mikrobiol Imunol. 2011 Sep;60(3):99-108. Czech.

PMID:
22132651
[PubMed - indexed for MEDLINE]
17.

Immunogenicity of booster vaccination with a virosomal hepatitis A vaccine after primary immunization with an aluminum-adsorbed hepatitis A vaccine.

Beck BR, Hatz CF, Loutan L, Steffen R.

J Travel Med. 2004 Jul-Aug;11(4):201-6.

PMID:
15541221
[PubMed - indexed for MEDLINE]
18.

Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis.

Moss RB, Mistry SJ, Konstan MW, Pilewski JM, Kerem E, Tal-Singer R, Lazaar AL; CF2110399 Investigators.

J Cyst Fibros. 2013 May;12(3):241-8. doi: 10.1016/j.jcf.2012.08.016. Epub 2012 Sep 17.

PMID:
22995323
[PubMed - indexed for MEDLINE]
19.

CXCR2 antagonists block the N-Ac-PGP-induced neutrophil influx in the airways of mice, but not the production of the chemokine CXCL1.

Braber S, Overbeek SA, Koelink PJ, Henricks PA, Zaman GJ, Garssen J, Kraneveld AD, Folkerts G.

Eur J Pharmacol. 2011 Oct 15;668(3):443-9. doi: 10.1016/j.ejphar.2011.03.025. Epub 2011 Mar 31.

PMID:
21458445
[PubMed - indexed for MEDLINE]
20.

Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist.

Leaker BR, Barnes PJ, O'Connor B.

Respir Res. 2013 Dec 16;14:137. doi: 10.1186/1465-9921-14-137.

PMID:
24341382
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk